The Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, met in New York on 28 November 2023, to discuss global health challenges and public health policies impacting biomedical innovation. 1 December 2023, New York City – The CEOs of leading biopharmaceutical companies met to focus on global health challenges and the importance...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and H3D Foundation have today announced a new three-year phase of their partnership, aiming to boost the skills and capacity needed to drive increased research and development of new medicines in Africa.
Read more
To mark World Antimicrobial Awareness Week (WAAW) 2023, the International Alliance of Patients’ Organizations (IAPO), the IAPO Patients for Patient Safety Observatory and its AMR Patient Alliance, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the World Medical Association (WMA), the International Council of Nurses (ICN) and International Pharmaceutical Federation (FIP), call for cross-sectoral collaboration to address the growing threat of AMR.
Read moreThis study by the Office of Health Economics (OHE) synthesizes existing evidence for the broad, socio-economic value of adult immunization programs, focusing on influenza, pneumococcal, herpes zoster (HZ), and respiratory syncytial virus (RSV) programs in ten countries (Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, United States). In a forthcoming publication, OHE will...
Read more
IFPMA’s Thomas Cueni to retire in April 2024, with Dr. David Reddy succeeding him as Director General
Read moreOn 6 November in Geneva, IFPMA delivered a statement at the seventh meeting of the Intergovernmental Negotiating Body on the Pandemic Accord.
Read moreOn 2 November, IFPMA and its member associations in South Korea, Singapore and Switzerland have welcomed the appointment of the Korean Ministry of Food and Drug Safety (MFDS) of South Korea, the Health Sciences Authority (HSA) of Singapore, and Swissmedic of Switzerland as the first three Listed Authorities under the WHO Listed Authorities (WLA) framework.
Read moreOn 2 November in New Delhi, India, IFPMA submitted a statement on Universal Health Coverage (UHC) at the 76th session of WHO Regional Committee for South-East Asia.
Read moreOn 26 October in Astana, Kazakhstan, IFPMA submitted a statement on health emergency preparedness, response, and resilience in the WHO European Region (2024-2029): Preparing for a new regional strategy and action plan (Preparedness 2.0). In preparation for the new regional strategy on Health Emergency Preparedness 2.0, we would like to share some of industry’s key...
Read moreOn 25 October in Astana, Kasakhstan, IFPMA submitted a statement on reaffirming commitment to health systems strengthening for universal health coverage, better outcomes, and reduced health inequalities.
Read moreOn 18 October 2023 at the 74th Session of the WHO Regional Committee for the Western Pacific in Manila, Philippines, IFPMA submitted a statement on agenda item 11: Health security.
Read moreOn 17 October in Geneva, IFPMA submitted a statement at the WIPO Standing Committee on the Law of Patents (SCP) 35.
Read more